A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer

BACKGROUND: The purpose of this randomised phase III trial was to evaluate whether the addition of simvastatin, a synthetic 3-hydroxy-3methyglutaryl coenzyme A reductase inhibitor, to XELIRI/FOLFIRI chemotherapy regimens confers a clinical benefit to patients with previously treated metastatic color...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Cancer
Autors principals: Lim, S H, Kim, T W, Hong, Y S, Han, S-W, Lee, K-H, Kang, H J, Hwang, I G, Lee, J Y, Kim, H S, Kim, S T, Lee, J, Park, J O, Park, S H, Park, Y S, Lim, H Y, Jung, S-H, Kang, W K
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2015
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4815882/
https://ncbi.nlm.nih.gov/pubmed/26505681
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2015.371
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars